3-methyl-N-[3-(1H-pyrazol-4-yl)-6-(1H-1,2,4-triazol-5-ylsulfanyl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine | 1025764-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methyl-N-[3-(1H-pyrazol-4-yl)-6-(1H-1,2,4-triazol-5-ylsulfanyl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine
• CAS: 1025764-39-9
• 化学式: C₁₅H₁₂N₁₀S₂
• 分子量: 396.459
• InChiKey: NMANOIVYNRCZGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  179
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20100249030A1

  公开（公告）日：2010-09-30

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.

  本发明涉及一种通过预先使用抗有丝分裂剂，然后再使用至少一种极化素激酶抑制剂来治疗癌症的方法。详细说明了在本发明治疗中有用的抗有丝分裂剂和极化素激酶抑制剂。
• IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
  申请人：Belanger David B.

  公开号：US20080139571A1

  公开（公告）日：2008-06-12

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
• US7511040B2
  申请人：——

  公开号：US7511040B2

  公开（公告）日：2009-03-31
• [EN] IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：SCHERING CORP

  公开号：WO2008057512A2

  公开（公告）日：2008-05-15

  [EN] In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
  [FR] Dans de nombreuses formes de réalisation, l'invention concerne une nouvelle classe de composés d'imidazopyrazine utilisés comme inhibiteurs de protéines kinases et/ou de kinases Aurora, des procédés de préparation de ces composés, des compositions pharmaceutiques comprenant un ou plusieurs de ces composés, des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés et des procédés utilisant ces composés ou compositions pharmaceutiques pour traiter, prévenir, inhiber ou soulager une ou plusieurs maladies associées aux protéines kinases et/ou aux kinases Aurora.
• [EN] ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT<br/>[FR] COMBINAISON D'AGENT ANTIMITOTIQUE ET D'INHIBITEUR DE L'AURORA KINASE COMME TRAITEMENT ANTI-CANCER
  申请人：SCHERING CORP

  公开号：WO2009017701A2

  公开（公告）日：2009-02-05

  The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.